Literature DB >> 17192859

Terbinafine-induced hepatic failure requiring liver transplantation.

Zeeshan Perveze1, Mark W Johnson, Raymond A Rubin, Marty Sellers, Carlos Zayas, Jody L Jones, Rosemary Cross, Kimberly Thomas, Bradley Butler, Roshan Shrestha.   

Abstract

Drug-induced liver disease accounts for about 50% of acute or subacute liver failure in the United States. United Network of Organ Sharing (UNOS) data suggest 8%-20% of liver transplantation in this country per year is for fulminant liver failure due to drugs. Even though the most common medication implicated in acute liver injury is acetaminophen (75%), there are numerous other drugs that are responsible for acute and chronic liver injury. A variety of antifungal medications are known to cause a wide range of liver injury from a mild hepatocellular-cholestatic injury pattern to acute/subacute liver failure. Terbinafine is one of the antifungals that have been associated with such liver injuries. We report a case of terbinafine-induced severe liver failure requiring liver transplantation. (c) 2006 AASLD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192859     DOI: 10.1002/lt.21034

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  14 in total

1.  Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo.

Authors:  M Ghannoum; N Isham; W Henry; H-A Kroon; S Yurdakul
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 2.  Systematic review of severe acute liver injury caused by terbinafine.

Authors:  Jun Yan; Xiaolin Wang; Shengli Chen
Journal:  Int J Clin Pharm       Date:  2014-07-02

3.  Terbinafine induced liver injury: a case report.

Authors:  Narendra S Choudhary; Hardik Kotecha; Neeraj Saraf; Dheeraj Gautam; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2014-04-03

4.  The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.

Authors:  Robert John Fontana; Elizabeth Theresa Cirulli; Jiezhun Gu; David Kleiner; David Ostrov; Elizabeth Phillips; Ryan Schutte; Huiman Barnhart; Naga Chalasani; Paul Brent Watkins; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

5.  Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation.

Authors:  Dustyn A Barnette; Mary A Davis; Noah Flynn; Anirudh S Pidugu; S Joshua Swamidass; Grover P Miller
Journal:  Biochem Pharmacol       Date:  2019-10-09       Impact factor: 5.858

6.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

7.  A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.

Authors:  Kartik Kumar; Anna Gill; Rachelle Shafei; Janine L Wright
Journal:  BMJ Case Rep       Date:  2014-12-05

Review 8.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

9.  Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5 % amorolfine lacquer.

Authors:  Jing Zhang; Sha Lu; Huaiqiu Huang; Xiqing Li; Wenying Cai; Jianchi Ma; Liyan Xi
Journal:  Lasers Med Sci       Date:  2016-06-23       Impact factor: 3.161

10.  Risk of oral antifungal agent-induced liver injury in Taiwanese.

Authors:  Wei-Yu Kao; Chien-Wei Su; Yi-Shin Huang; Yueh-Ching Chou; Yi-Chih Chen; Wen-Hung Chung; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Jaw-Ching Wu
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.